An interventional study of Bupivacain and Ultrasound in Thoracic and Pain, sponsored by Yasser S Mostafa, MD. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Yasser S Mostafa, MD · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.
Among the 146 studies testing bupivacaine in Pain, this one is the 108th largest by enrollment, is one of 6 that started in 2025, is one of 46 with no phase, and was the 135th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 40–75
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 22 · Phase 4 55
First in 2002; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 63 across the 146 interventional studies. Of the 102 that completed or were terminated, 53 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 146 have an industry lead sponsor. The 10 most frequent:
Yasser S Mostafa, MD is the lead sponsor of 4 studies on the registry; none are open to participants now.
Yasser S Mostafa, MD has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
8 of the studies testing bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07631416Sohag UniversityLumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia | 2026-11-28 |
| NCT06004882M.D. Anderson Cancer CenterPeripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study | 2027-01-31 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 146 studies testing bupivacaine in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the current study is to compare the efficacy of the analgesic effect of ultrasound-guided unilateral Rhomboid intercostal and sub serratus plane block (RISS) versus Serratus anterior plane block (SAPB) in Thoracotomy incision.
Open thoracotomy is commonly considered to be one of the most agonizing surgical operations. Pain following thoracotomy greatly impedes patient recovery and postoperative respiration. The pain experienced after a thoracotomy can originate from various factors, including the surgical incision, injury to the ribs and intercostal nerves, manipulation of the pleura and lung tissue, and the placement of a drainage tube.Recent advances in regional anesthesia techniques have aimed to provide more targeted and effective pain relief. Among these, ultrasound-guided fascial plane blocks, such as the rhomboid intercostal sub-serratus plane (RISS) block and the serratus anterior plane (SAP) block, have emerged as promising options. Both blocks target the thoracic nerves, but they differ in their anatomical approach and potential analgesic effects Postoperative pain was not only related to a comfortable recovery but also related to postoperative complications including pulmonary dysfunction, so the management of postoperative pain is an important part of the care of post operation.
Regional anesthesia techniques have been shown to have a good effect on postoperative analgesia and helps patients gain early recovery after operation.
Serratus anterior plane block (SAPB) is an easy, and safe method used for blockade of the sensory plane of the lateral cutaneous branch of the intercostal nerve (T2-T9).
The Serratus anterior plane block targets the lateral cutaneous branches of the thoracic intercostal nerves, which arise from the anterior rami of the thoracic spinal nerves and run in a neurovascular bundle immediately inferior to each rib. At the midaxillary line, the lateral cutaneous branches of the thoracic intercostal nerve traverse through the internal intercostal, external intercostal, and serratus anterior muscles innervating the musculature of the lateral thorax. These branches of the intercostal nerves travel through the two potential spaces described above.
The "Rhomboid intercostal and sub serratus plane block" (RISS) is a relatively newer block technique whose efficacy was documented in patients undergoing thoracic surgeries.
The RISS plane block involves the injection of local anesthetics into fascial planes, theoretically allowing for catheter placement to achieve continuous analgesia. Successful RISS plane blocks have been reported in various procedures, including lung transplantation, radical mastectomy, and nephrectomy, strongly suggesting favorable outcomes in postoperative pain relief.
In 2016, Elsharkawy et al. introduced a RA technique known as the rhomboid intercostal block (RIB). Rhomboid intercostal block involves injecting a local anesthetic into the upper intercostal muscle plane beneath the rhomboid muscles, providing analgesia to both the anterior and posterior thorax.Based on past studies, investigators found that RISS and SAPB are effectively decrease total opioid consumption, so investigators hypothesized one of them is the best.
Statistical analysis:
Statistical analysis will be conducted using IBM SPSS Statistics 22(IBM Corp., Armonk, NY, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p \< 0.05 will be deemed to be statistically significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A high- frequency linear ultrasound transducer will be placed longitudinally (in the sagittal plane) on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe will be slightly rotated to obtain an oblique parasagittal plane. The following landmarks will be identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). The rhomboid major muscle will be distinguished at the level of the T6 and T7 vertebrae, below the trapezius muscle.
Drug: Bupivacain · Device: Ultrasound
* The patient will be positioned laterally, and routine skin disinfection and draping will be completed. * Investigators also will use a linear ultrasound probe (Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID: 1385, Nile medical center, service@nilemed.net) for performing the block. * The fifth rib will be identified along the mid-axillary line to locate the deep serratus anterior muscle and the superficial latissimus dorsi muscle. * The needle will be inserted between the fifth and fourth ribs using a 22G (50 mm) puncture needle.
Drug: Bupivacain · Device: Ultrasound
After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
Also known as: Marcaine 0.25%
A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
Total opioid consumption
in microgram
Time frame: 24 hours postoperatively.
Total intraoperative opioid consumption
in microgram
Time frame: from begining of operation till 5 minutes after extubation
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: Immediately after the procedures
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: Immediately after the procedures
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 1 hour postoperatively.
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 1 hour postoperatively.
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 3 hours postoperatively.
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 3 hours postoperatively.
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 6 hours postoperatively.
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 6 hours postoperatively.
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 12 hours postoperatively.
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 12 hours postoperatively.
Visual analog pain score at rest
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 24 hours postoperatively.
Visual analog pain score at cough
Ranging from 0 indicating no pain to 10 indicating extreme pain
Time frame: 24 hours postoperatively.
Time of first rescue analgesic
in minutes
Time frame: 5 minutes before first analgesic request
Baseline Heart rate
Beat / minute
Time frame: 5 minutes before anesthesia
Intraoperative Heart rate
Beat / minute
Time frame: every 30 minutes along operation
Baseline mean arterial blood pressure
mmHg
Time frame: 5 minutes before anesthesia
Intraoperative mean arterial blood pressure
mmHg
Time frame: every 30 minutes along operation
Baseline oxygen saturation
percentage with pulse oximetry
Time frame: 5 minutes before anesthesia
Intraoperative oxygen saturation
percentage with pulse oximetry
Time frame: every 30 minutes along operation
Total length of stay in hospital
in days
Time frame: 1-2 days
Patient satisfaction score
5 degree Likeart scale where 1 Extremely satisfied to 5 Extremely not satisfied
Time frame: 12 hours after end of operation and extubation
Incidence of hematoma
Yes or no
Time frame: 30 minutes after nerve block
Incidence of local anesthetic toxicity
Yes or no
Time frame: 30 minutes after nerve block
Incidence of nausea
Yes or no
Time frame: 24 hours postoperative
Incidence of vomiting
Yes or no
Time frame: 24 hours postoperative
Ramsay sedation score
From 1 to 5 (1 Awake; agitated or restless or both - 2 Awake; cooperative, oriented, and tranquil - 3 Awake but responds to commands only - 4 Asleep; brisk response to light glabellar tap or loud auditory stimulus - 5 Asleep; sluggish response to light glabellar tap or loud auditory stimulus) Asleep; no response to glabellar tap or loud auditory stimulus
Time frame: 24 hours postoperative
Age
in years
Time frame: 5 minutes before entering operation department
Sex
Male of female
Time frame: 5 minutes before entering operation department
Plan to share: No
Ran from Feb 2025 to primary completion in May 2026, 15 months.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 15 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Sep 2026 → May 2026 and completion Oct 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine
Yasser S Mostafa, MD